Dose escalation during consolidation therapy of de novo AML, including myeloablative chemotherapy supported with autologous peripheral blood stem cell transplantation (aPBSCT), continuously improved outcome. Therefore, quality control of transplants is getting increasing interest. We studied leukapheresis products (LPs), consecutively collected during postremission treatment of 20 patients with de novo AML for minimal residual disease (MRD) by 5-parametric flow cytometry and for myelodysplasia (MDS)-associated alterations by paired lineage-selected colony assays for colony-forming units-megakaryocytes (CFU-mega) and burst-granulocytes-monocytes colony-forming units (CFU) to evaluate the predictive value of these transplant-associated parameters on outcome. We defined the leukemia-associated immunophenotype at diagnosis and studied the impact of MRD detection in LPs collected after double induction with TAD (thioguanine, daunorubicin, cytarabine) and HAM (mitoxantrone, high-dose cytarabine, n = 18 patients) and TAD consolidation treatment (n = 20 patients) on outcome after aPBSCT. The level of MRD in the transplants correlated with the relapse-free survival (RFS) using a cut-off level of 1 × 10 −3 residual leukemic cells. The median RFS was 6 months for the group with у1 × 10 −3 residual leukemic cells and has not been reached in the group with low MRD levels (Ͻ1 × 10
Introduction
Dose escalation has continuously improved the outcome in acute myeloid leukemia (AML) during the last 10 years. [1] [2] [3] [4] For many years, myeloablative chemotherapy and autologous bone marrow transplantation (aBMT) have been successfully used for dose intensification during postremission treatment of AML. 5, 6 The feasibility of stem cell mobilization after consolidation treatment of de novo AML in first complete remission (CR) and the significantly faster bone marrow recovery following autologous peripheral blood stem cell transplantation (aPBSCT) in comparison with aBMT, have made aPBSCT more and more attractive also for elderly patients. 1, 7, 8 The use of autologous transplants in AML is still being discussed because of the risk of minimal residual disease (MRD) in the transplant. Brenner et al 9 demonstrated that genemarked AML cells in autologous transplants may be involved in AML relapse. On the other hand, MRD in transplants of AML patients may also reflect insufficient blast clearance following induction and consolidation chemotherapy. This is supported by the data showing a significant correlation between MRD in pretransplant bone marrow and corresponding high relapse rates. 10 However, data of MRD in transplants and corresponding outcome are still missing. Up to now, little is known about the functional behavior of the presumably normal autologous non-leukemic hematopoietic progenitor cells (HPC) used for bone marrow rescue after myeloablative chemotherapy in AML patients without clinical, morphological or cytogenetic evidence for myelodysplastic syndrome (MDS) at diagnosis. Two observations may indicate that, especially in AML, such non-leukemic progenitors in the transplant could already express MDS-like aberrations. Firstly, MDS following aPBSCT is a clinical problem, which is already recognized in lymphoma and plasmocytoma patients. [11] [12] [13] [14] [15] Secondly, the incidence of developing MDS seems to depend on the duration and intensity of pregraft chemotherapy and on single drugs known to be involved in MDS induction. 16 In the present study, we used unpurged back-ups and unpurged transplants collected following double-induction and consolidation treatment of de novo AML to investigate two major transplant characteristics in follow-ups: MRD and lineage-selected proliferation of non-leukemic progenitors, especially of megakaryocytic progenitors. Megakaryocytic colony growth was already shown to be impaired in MDS. [17] [18] [19] We used 5-parametric flow cytometry to monitor MRD in transplants and CFU assays to determine lineage-selected colony growth. Both transplant characteristics were correlated with the outcome of AML patients in order to assess their value in predicting relapse. MRD in the transplant was additionally compared to MRD in the pregraft bone marrow to evaluate the most suitable stem cell source for immunophenotypical MRD detection.
Materials and methods
Twenty-seven patients aged 15 to 60 years with de novo AML entering consecutively our institution were enrolled in the study protocol on the basis of intent to treat. Diagnosis of AML was made according to French-American-British (FAB) group revised criteria. 20 In none of the patients cytogenetic aberrations at diagnosis were suggestive of a pre-existing myelodysplastic syndrome (MDS). Twenty patients (69%) without an HLA-identical sibling who achieved CR after double-induction chemotherapy were considered eligible to receive consolidation chemotherapy followed by an intensive postremission chemotherapy with a myeloablative conditioning regimen and aPBSCT. One transplantation-associated death was observed.
Leukemia-specific aberrant immunophenotype was defined at diagnosis from bone marrow samples (n = 20) and followed in the back-up collected after double-induction (30 leukapheresis (LPs) within 18 leukapheresis cycles (LCs)) in the transplants collected following consolidation (30 LPs within 13 LCs) or after an additional mobilization cycle with cyclophosphamide (CY) (16 LPs within 7 LCs), in the pregraft bone marrow (n = 18 patients, two sicca punctions) and in the post-graft bone marrow (19 patients), 4 to 10 weeks after aPBSCT, when criteria for CR were assessed in the peripheral blood. Colony growth was studied with paired lineage-selected CFU-mega and CFU assays in all LPs. Data for MRD and from CFU assays are reported for 20 patients. These transplant-associated characteristics were correlated with the 19 patients being available for follow-up (median time of 35 months, range 13 to 54 months). Median relapse-free survival (RFS) was 30 months at 4 years, overall survival 31 months at 4 years.
Treatment
Double-induction chemotherapy consisted of one cycle TAD, daunorubicin (60 mg/m 2 day 1 to 3), Ara-C (100 mg/m 2 day 1 and 2, twice daily 100 mg/m 2 day 3 to 8) and thioguanine (twice daily 100 mg/m 2 day 3 to 9) and one cycle of HAM, cytarabine (twice daily 3 g/m 2 day 1 to 3) combined with mitoxantrone (20 mg/m 2 day 3 to 5). 21 When CR was achieved, patients received a TAD consolidation cycle. As intensive consolidation therapy, high-dose busulfan (4 mg/kg day −9 to −6) combined with CY (60 mg/kg day −5 to −2) was given followed by aPBSCT on day +1. 22 The median time interval from first CR to aPBSCT was 8 weeks (range 5 to 12 weeks).
Stem cell mobilization
G-CSF (Neupogen; Amgen) was given after HAM and TAD consolidation chemotherapy to mobilize PBSCs. Daily G-CSF application was started on day 2 after end of chemotherapy (5 g/kg s.c.). A further mobilization course with 2 g/m 2 CY day 1 was applied when enough CD34 positive cells could not be harvested during HAM and TAD mobilization (n = 7 patients).
Harvesting, cryopreservation, thawing and retransfusion of PBSCs
Stem cells were collected with a continuous flow blood cell separator, either a Cobe Spectra Apheresis System (Munich, Germany) or a Fenwal CS 3000 (Munich, Germany). During leukapheresis a total volume of 8-12 1 at a flow rate of 50-70 ml/min was processed. Leukaphereses were done during recovery following chemotherapy when CD34 counts were Ͼ3 × 10 3 /ml. Daily leukaphereses were necessary during 1 to 5 subsequent days within a mobilization cycle corresponding to a median of 2.0 leukaphereses per mobilization with HAM and TAD consolidation or CY, respectively.
The apheresis product was mixed with an equal volume of minimal essential medium containing 20% dimethylsulfoxide (DMSO, Merck, Darmstadt, Germany) and immediately transferred into freezing bags and vials containing 1 ml cell suspension (Cryocyte freezing container, Fenwal) and frozen to −100°C with a computer-controlled cryopreservation device (Cryoson BV-6, Cryoson Deutschland GmbH, Schö llkrippen, Germany). The frozen bags and vials were stored in liquid nitrogen at −196°C until use.
The vials for MRD and paired lineage-selected CFU studies were thawed in a 40°C waterbath with addition of 1 ml DNAse stock-solution (final concentration of 3.6 g/ml) and 8 ml PBS. Before plating mononuclear cells (MNC) of the LPs, cells were subjected to two successive low-speed centrifugations to remove platelets which could be a source of growth inhibiting factors (TGF). 23, 24 The transplants were thawed in a 40°C waterbath. A mean of 1.33 × 10 6 CD34 positive cells per kg (range 0.1 to 2.9 × 10 6 ) and 1.38 × 10 5 CFU-GM/kg (range 0.14 to 2.8 × 10 5 ) were retransfused.
Bone marrow morphology
Bone marrow aspirates were taken after each induction and consolidation cycle and every 3 months, following transplantation. The first post-transplant aspiration was performed directly after peripheral remission parameters were achieved, 4 to 10 weeks after transplantation. Diagnosis of MDS was made according to typical morphological features. 25 Complete remission was defined according to the Cancer and Leukemia Group B.
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Immunophenotyping at diagnosis and for detection of minimal residual disease
Heparinized bone marrow aspirates for the initial diagnosis were analyzed for antigen coexpression by flow cytometric analysis of 20 000 to 50 000 cells for each of the following double and triple staining fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), and peridinin chlorophyll (PerCP) or tandem conjugates of PE with indodicarbocyanine (PE/Cy5) with directly fluorochrome-conjugated monoclonal antibodies (MoAB): HLA-DR/CD14/CD45, CD8/CD4/CD3, CD7/CD1a/ CD2, CD10/CD5/CD19, CDw65/CD33, CD34/CD13/CD20, CD41/anti-glycophorin A, CD42b/CD15, anti-kappa/antilambda/CD19, anti-IgM/CD22, anti-terminal deoxynucleotidyl transferase (TdT)/CD22(CD79a upon availability)/CD3, anti-myeloperoxidase (MPO)/anti-IgM. Individual three-color combinations according to the malignant phenotype were analyzed for the detection of residual disease.
Staining for cell surface immunofluorescence:
For flow cytometric immunophenotyping of surface antigens unseparated bone marrow (100 l) or apheresis product (10 6 cells/100 l) was incubated for 15 min on ice with saturating concentrations of the fluorochrome-conjugated antibodies. Cells were washed three times (5 min, 425 g) with 3 ml of Dulbecco's phosphate-buffered saline without Ca++ or Mg++ (PBS, Biochrom, Berlin, Germany) prior to incubation with MoAB for staining of surface immunoglobulins. The MoAB CD1a (clone SFCI19Thy1A8), CD10 (J5), CD13 (366), CD14 (RMO52), CD33 (906), CD41 (P2), CD42b (SZ2), anti-glycophorin A (D2.10) and anti-HLA-DR (B8.12.2) were obtained from Coulter-Immunotech (Hamburg, Germany). MoAB against CD3 (SK7), CD4 (SK3), CD5 (L17F12), CD7 (4H9), CD20 (L27), CD22 (S-HCL-1), CD34 (8G12) and CD45 (2D1) were obtained as R-PE or PerCP conjugates from Becton Dickinson (Heidelberg, Germany). MoAB against CD15 (DU-HL60-3) and CD19 (SJ25-C1) were obtained as R-PE conjugates from Sigma (Deisenhofen, Germany). Antibodies against CD2 (G11) and CD65 (VIM2) were obtained from Caltag (Burlingame, CA, USA). Anti-CD8 (OKT8) antibody, directly conjugated to FITC, was obtained from Ortho (Neckargmü nd, Germany). R-PE conjugated anti-CD79a antibody (HM 57) and FITC and R-PE conjugated rabbit F(abЈ)2-fragments of anti-human kappa and lambda, respectively, immunoglobulin light chains were obtained from Dako (Hamburg, Germany). FITC and R-PE conjugates of goat F(abЈ)2-fragments of antihuman IgM were from Tago (Burlingame, CA, USA). Antimyeloperoxidase (H-43-5) was obtained as a FITC conjugate from Fix&Perm (Vienna, Austria) and anti-TdT as a mixture of three different FITC-conjugated MoAB from Supertech (WAKChemie Medical, Bad Homburg, Germany). After the incubation, blood samples were treated for 10 min with the erythrocyte lysis solution from Becton Dickinson (FACSlyse), then washed twice (5 min, 425 g) with 3 ml of PBS. The cells were then stored on ice in the dark until analysis. Sample preparation and analysis were always performed within 4 h of venipuncture.
Staining for intracellular immunofluorescence:
For simultaneous flow cytometric analysis of intracellular expression of the triple color combination of TdT, CD22 or CD79a, and CD3 or the dual color combination of anti-MPO and anti-IgM, unseparated bone marrow or apheresis product (50 l) was first fixed for 5 min at room temperature using a commercial solution (Fix&Perm reagent A). The cells were then washed once with PBS. The pellet was resuspended in 200 l of a permeabilization medium (Fix&Perm reagent B) and then incubated with saturating concentrations of fluorescent dye conjugated antibodies for 15 min on ice and finally washed with PBS. The cells were then stored on ice in the dark until analysis.
Flow cytometric analysis:
Following staining of the cells, the cellular light scatter signals and three fluorescence signals (20 000 to 50 000 nucleated cells per sample) were analyzed in list mode at 1024 channel resolution using forward scatter as the trigger parameter on a FACScan flow cytometer (Becton Dickinson). The photomultiplier gains and compensation were adjusted using FITC and R-PE coated microbeads (Becton Dickinson) and peripheral blood lymphocytes triplestained with antibodies against CD3, CD4, and CD8 as a biological control. Bivariate dot plots were produced for all combinations of the 5-parametric list mode data following pseudocolor coding for typical light scatter regions using CELLQuest (Becton Dickinson) for the visual detection of malignant phenotypes. 27 The percentage of abnormal cells was then calculated following multidimensional gating using Paint-a-Gate Pro software (Becton Dickinson). We defined the following abnormal immunophenotypes: Cross lineage antigen expression (coexpression of lymphoid markers on myeloid blast cells), asynchronous antigen expression (expression of an abnormal sequence and density of myeloid and monocytic antigens, such as early (CD33) and late antigens (CD65) in varying densities), antigen over-and underexpression (abnormal expression of a certain antigen on leukemic cells) and aberrant light scatter (myeloid cells displaying aberrant light-scatter properties). Leukemic cells with aberrant light scatter could be clearly separated from monocytes according to the characteristic monocytic SSC and CD14 antigen expression.
Clonogenic progenitor assay
Colony-forming units (CFU), ie the total number of mixed colony-forming units (CFU-mix), granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E) and erythroid colony-forming units (5 CFU-E correspond to 1 BFU-E) were evaluated using commercially available media (Methocult H 4431, Stemcell Technologies, Vancouver, Canada). Briefly, 1 ml aliquots of thawed MNC cells were plated at concentrations of 5 × 10 4 /ml, in triplicates, in 35 mm culture dishes (Falcon; Becton Dickinson Labware) and incubated at 37°C in a humidified incubator with 7% CO 2 and 5% O 2 . After 14 days of culture the total number of CFUs was counted under an inverted microscope.
Megakaryocytic colony growth from hematopoietic progenitor cells was studied in a serum-free, semisolid collagen containing medium (EASY-MEGA, Hemeris, Sassenage, France) with the addition of an optimized cytokine cocktail for human megakaryocytic progenitor culture. First, 0.8 ml human purified collagen (final concentration 0.1%) was added to 2.4 ml medium (final concentrations: 1.5% bovine serum albumin, 2 mM L-glutamine, 100 M 2␤ mercaptoethanol, 0.1 mM Na pyruvate, 250 M CaCl 2 , 4% lipid mixture, 10 g/ml bovine pancreatic insulin, 300 g/ml human transferrin in Iscove's modified Dulbecco's medium) and immediately vortexed. Finally, 20 l cell suspension, 20 l RPMI and 60 l cytokine cocktail (rhIL3 2.5 ng/ml, rhIL6 10 ng/ml (R&D Systems, Abingdon, UK), rh MGDF 50 ng/ml (kindly provided by Amgen, Thousand Oaks, CA, USA) were added. After mixing, the solution was dispensed rapidly in three 35 mm non-treated culture Petri dishes at 1 ml per dish. The gels were cultured for 14 days at 37°C in a humidified incubator with 7% CO 2 and 5% O 2 .
For staining, gels were fixed at room temperature with methanol-acetone for 5 min and subsequently incubated first with anti-CD41 MoAB (Hemeris) or an irrelevant control antibody (Dako, Glostrup, Denmark) and then with 300 l diluted APAAP complex (Dianova, Hamburg, Germany) per slide for 30 min at room temperature. Finally, 400 l alkaline phosphatase substrate (Dianova) per slide was added and incubated at room temperature for 20 min. After staining gels were washed in PBS and counterstained with Mayer's hematoxylin for 30 s.
CFU-mega, ie colonies of 5 to 20 CD41 + cells and BFUmega, ie colonies of Ͼ20 cells were evaluated after 14 days of culture. The ratio of BFU-mega to CFU-mega was relatively constant throughout our study (1 BFU-mega on 5 to 12 CFUmega). Therefore, the number of total CFU-mega is reported as the sum of BFU-mega and CFU-mega. The ratio of CFUmega and CFU was calculated to document changes in the proportion of clonogenic MPs in the LPs and to correct for the decreasing clonogenicity within consecutive apheresis cycles.
Additional paired analyses were done with LPs collected from patients without bone marrow involvement of their malignant disease (n = 10), receiving chemotherapy for the first time to validate the CFU-mega assay (control group). To exclude a significant impact of MRD on the lineage selection potential of normal hematopoietic progenitor cells, back-up leukapheresis samples of patients without detectable MRD in LPs and in CCR were mixed with 0.1 to 0.5% autologous leukemic blast cells for in vitro culture (paired lineage-selected colony assays).
Statistical methods
Kaplan-Meier life-tables were constructed for relapse-free survival and overall survival. Relapse-free survival for MRD high and low groups were compared by means of a one-sided logrank test with surviving patients (actual follow-up). The MannWhitney test (two-sided) was used to analyze the CFU mega/CFU ratio in the relapsing group, the survivors and the control group, as well as the number of residual leukemic cells in the back-ups and in the transplants.
Results
Phenotype of blast cell population
At diagnosis an aberrant leukemia-specific immunophenotype could be identified in 18 of 20 cases (90%). Two cases displayed immunophenotypes also found in low frequency within the normal subpopulation of progenitor cells, however, expressed an aberrant light scatter and therefore be included in flow cytometric MRD analysis. The aberrant immunophenotypes are listed in Table 1 . Cross-lineage antigen expression was detected in 11 cases (TdT, CD7, CD5, CD22, CD79a), antigen overexpression in 10 cases (CD4, CD33, CD34, CD65, HLA-DR), antigen underexpression in three cases (CD45), asynchronous coexpression of antigens in seven cases (CD33/CD65, CD13/CD34, CD13/CD45, CD4/CD45) and an aberrant light scatter in six cases (Table 1 ). In 13 of 20 patients (65%) two or three criteria could be used for the definition of the aberrant leukemia-associated phenotype.
Detection of minimal residual disease and outcome
The mean number of residual leukemic cells within LPs with detectable MRD (28 LPs in 15 LCs) was 5.2 × 10 −3 (range 0.4 × 10 −3 to 27 × 10 −3 ), following HAM 8.4 × 10 −3 (range 1.6 × 10 −3 to 27 × 10 −3 ) and significantly less in the transplants collected following TAD or CY 3.2 × 10 −3 (range 0.4 × 10 −3 to 6.3 × 10 −3 , P Ͻ 0.02). To evaluate the impact of different MRD levels on relapse-free survival we used different cut-off levels (0.5 × 10 −3 , 1 × 10 −3 , 2 × 10 −3 ). A cut-off level of 1 × 10 −3 displayed the highest statistical significance. Using this threshold, the transplants of 15 patients (75%) with a median number of 1 × 10 −4 residual leukemic cells (range not detectable to 6 × 10 −4 ) were estimated MRD 'low' and the transplants of five patients (25%) with a median number of 4.2 × 10 −3 residual leukemic cells (range 1.5 × 10 −3 to 6.3 × 10 −3 ) were estimated MRD 'high'.
Incidence of relapse and RFS correlated with the number of residual leukemic cells in the transplants, but was not correlated with the time interval between first CR and aPBSCT. This time interval was variable due to additional mobilization cycles with CY (n = 7) or different time intervals until CR was achieved. In the group with Ͻ1 × 10 −3 residual cells, five of 14 patients (35%) relapsed, whereas all five patients relapsed in the group with Ͼ1 × 10 −3 residual leukemia cells. The median RFS was 6 months for the group with high MRD levels, the median RFS of the group with low MRD levels has not been reached (P = 0.003) (Figure 1 ). The diagnostic sensitivity and specificity to detect patients at risk of relapse by the leukemia-associated immunophenotype was 50% and 100%, respectively.
Only two of the five patients with high levels of MRD in the transplant also expressed high levels of MRD in the bone marrow. MRD was detectable in five of 18 bone marrow aspirates (1.6 × 10 Relapse-free survival in AML patients in first CR depending on the number of residual leukemia cells in the transplant detected by 5-parametric flow cytometry. Ͼ1 × 10 −3 leukemia cells (n = 5) with a median survival of 6 months; Ͻ1 × 10 −3 leukemia cells (n = 14).
Figure 2
Megakaryocytic colony growth in the back-up leukapheresis products (LP) collected after mobilization with HAM and in the transplant LPs collected after mobilizations with TAD consolidation or cyclophosphamide (Cy) has been characterized by the ratio CFU mega/CFU from paired lineage-selected colony assays (n = 13). The median ratio CFU mega/CFU was 0.21 in LPs collected for back-up (range 0.01 to 0.56) and 0.24 in LPs collected as transplants (range 0.02 to 0.70, P = 0.78).
Bone marrow morphology in follow-up
All 20 patients achieved morphological CR after doubleinduction treatment without any direct evidence of a myelodysplastically impaired bone marrow. Further bone marrow aspirates were taken every 3 months following aPBSCT, with the first aspirates being taken after peripheral complete remission, 4 to 10 weeks after aPBSCT. In the first postgraft aspirate, all patients met the criteria for morphological CR. At relapse morphological changes complied with the criteria for MDS in five patients. MDS (1 × refractory anemia, RA, 3 × refractory anemia with ringed sideroblasts, RARS, 1 × refractory anemia with excess blasts, RAEB) was diagnosed 5 to 18 months after aPBSCT and 5 to 14 months before transition into AML. The other five relapsing patients suffered from a primary AML relapse. Three patients relapsing with MDS have shown additional chromosomal aberrations.
Colony growth in leukapheresis products
Colony growth was consecutively followed in single LPs. Megakaryocytic colony growth in a serum-free test system, supplied with rhIL3, rhIL6 and rhMGDF provided highly reproducible results. We observed stepwise decreasing median CFU-mega counts within consecutive mobilization cycles. Median CFU-mega counts in LPs following HAM were 18.5 (range 1 to 51), following TAD consolidation 16.0 (range 1 to 69) and following CY 11.2 (range 1 to 16) with a P value Ͻ0.01 for CFU-mega HAM vs CFU-mega CY. These results were paralleled by a decreasing mean number of CFUs within consecutive mobilization cycles. The median number of CFUs following HAM was 122.9 (range 19 to 236) following TAD 109.8 (range 19 to 346) and 39 (range 10 to 68) following CY (P Ͻ 0.01).
To correct for the stepwise decreasing clonogenicity and for varying numbers of seeded CD34 positive cells, a ratio of CFU-mega to CFU was calculated to record differences in the proportion of megakaryocytic progenitors (MPs) within single LPs. The ratio was rather constant within single LPs of an apheresis cycle (maximal deviation ± 21%). In contrast to the invariably high ratio CFU-mega/CFU in the control group (mean ± s.d., 0.92 ± 0.16), ie patients without bone marrow involvement by underlying solid tumors, the ratios CFUmega/CFU in LPs of AML patients during first CR (mean ± s.d. 0.24 ± 0.19) were highly variable and significantly lower than in the standard group (P Ͻ 0.001). Whereas clonogenicity decreased in both lineage-specific assays with the number of preceding chemotherapy cycles, the median ratios CFUmega/CFU did not substantially change within consecutive mobilization cycles (Figure 2 ). Megakaryocytic colony growth was not disturbed by leukemic blast cells added to leukapheresis samples.
Figure 3
CFU-mega growth in the transplants of 19 AML patients depending on outcome within a mean observation time of 35 months (range 13 to 54 months). To correct for a stepwise decreasing clonogenicity during induction and consolidation treatment the quotient CFU-meg/CFU is given from paired lineage-selected CFU assays. Control values for the quotient CFU-mega/CFU were obtained from transplants of patients with solid tumors and no bone marrow involvement.
CFU-mega and outcome
Low CFU-mega/CFU ratios (Ͻ0.12) were not correlated with a delayed remission or a delayed aPBSCT. Additional mobilization cycles with CY were necessary both in the CCR group and in the relapsing group. Platelets recovered at a median time interval of 59 days (range 16 to 92 days) to Ͼ100/nl. Platelet recovery was not significantly different in the group of patients relapsing with MDS in comparison with patients being in CCR or relapsing with AML (P = 0.23).
To evaluate a possible pathophysiological impact of low and high ratios CFU-mega/CFU megakaryocytic colony growth was correlated with outcome. Several cut-off levels (0.06, 0.12, 0.18 and 0.24) for the ratios CFU-mega/CFU were tested for statistical significance concerning RFS to define a threshold. The ratio 0.12 displayed the highest statistical significance (P = 0.001) (Figure 3) . The pathophysiological relevance of low ratios (Ͻ0.12) in the transplant (n = 7 patients) is supported by the frequent occurrence of a MDS prior to the transformation into an AML in five of these seven cases. Only three relapses with AML occurred in the group with ratios CFU-mega/CFU Ͼ0.12. Thus, seven of 10 patients (70%) with a high risk of relapse could be detected. Additionally the median time to relapse was significantly different between the group with low vs high CFU mega/CFU ratios, 17.3 months vs 8.0 months (P Ͻ 0.001). Whereas median ratios CFUmega/CFU were well correlated with outcome, the number of CFUs, CFU-GM and BFU-E were not predictive for relapsefree survival. The corresponding P values for RFS were 0.12, 0.07 and 0.09 by using optimized thresholds as for the ratio CFU-mega/CFU. Combining both predictive variables in the transplant, MRD and ratio CFU-mega/CFU, five relapsing patients (50%) expressed both transplant-associated risk profiles, indicating a high coincidence. Two additional relapsing patients being MRD low in the transplant, that means 20% more, could be detected to be at risk of relapse by a low ratio CFU-mega/CFU.
Discussion
The study shows, for the first time, that different levels of immunophenotypically detected MRD in the transplants significantly correlate with the probability of relapse. Although RFS was significantly different between the MRD Ͻ1 × 10
and у1 × 10 −3 (P = 0.003), half of the relapses could not be detected. Failure to identify patients with a high probability of relapse may depend on: (1) the sensitivity of the method; (2) the sampling technique; (3) the cell source; and (4) the inability to detect the immunophenotype of the leukemic stem cell. [28] [29] [30] However, immunophenotyping is the most widely applied technique, as more than 80% of the AML cases may express an abnormal leukemia-specific immunophenotype. 31 Previously published studies reporting the detection of MRD in AML are difficult to compare as they use different methods. [32] [33] [34] [35] A possible advantage of different culture techniques for bone marrow-derived progenitor cells to detect MRD by leukemia colony-forming units (CFU-L) remains to be evaluated. 36, 37 The study compared predictivity of MRD detection in the pretransplant bone marrow aspirate and the corresponding transplant. Using the same cut-off level, the predictive value of MRD detection was significantly higher for the transplants. The discrepancy may be due to the sampling technique of bone marrow aspirates or a selective mobilization of leukemic cells into the peripheral blood. Yet, MRD in the bone marrow detected by flow cytometry appears indeed to be of prognostic value as shown already by other study groups. 10, 34, 35 Immunophenotypical MRD analysis in the first bone marrow aspirate following aPBSCT failed to reliably detect patients at risk of relapse. These MRD results indicate an effective cytoreduction by BU/CY, probably below a critical detection level. Thus an early search for MRD in the bone marrow by immunophenotyping, shortly after achieving remission criteria, seems not to be of value. Nevertheless, monitoring of MRD in CR over longer time periods is recognized as an important tool for identifying patients with a high probability of relapse.
31
Up to now, MRD in the pretransplant bone marrow has been considered to be the most important criterion defining stem cell quality in autologous transplants. Results from the paired lineage-selected CFU assays now give evidence that relapses in AML may also be related to a functionally altered remission hematopoiesis, characterized by a highly decreased CFU-mega growth in the transplant. The pathophysiological impact of this observation is underlined by the frequent occurrence of MDS at relapse in cases with defective megakaryocytic growth in the transplant (five of seven patients, 71%). This defect in the lineage selection was shown not to be associated with an incomplete hematopoietic reconstitution or myelodysplastic features following aPBSCT. Therefore, altered pretransplant CFU-mega growth is indicative for a clinically inapparent preleukemic disposition of the remission hematopoiesis, ie a pre-MDS. This may already be present at diagnosis or induced by sequentially applied dose-intensive chemotherapy. Altered megakaryocytic colony growth, as well as low CFU-mega counts, were frequently observed in studies investigating colony growth in bone marrow aspirates of patients with MDS. Reduced CFU-mega numbers may be paralleled by decreased BFU-E and CFU-GM numbers in the bone marrow of patients with MDS. [17] [18] [19] An altered megakaryocytic colony growth as preleukemic disposition of the remission hematopoiesis may be easily integrated within available data. Firstly, an altered in vitro colony growth, ie CFU-GM, of bone marrow-derived progenitor cells was found in patients relapsing with AML. 38 Using PBSC for paired lineage-selected CFUs the number of CFU-GM, or BFU-E was not predictive for relapse, as shown in the present study. Secondly, the observation of a pre-MDS in the remission hematopoiesis is in agreement with the finding that a post-transplantation MDS may occur very early in patients with AML, as shown by X-chromosome inactivation patterns. 39 The presence of a clonal remission hematopoiesis or a clinically defined pre-MDS in the transplant would limit autologous transplantation procedures and would explain the success of allogeneic transplantation as well as cyclic maintenance therapy. 1, 5, 21 Studies are ongoing to define remission hematopoiesis on a molecular level.
Autologous BMT or aPBSCT may carry the risk of secondary MDS or AML which are already known as complications in patients with lymphomas or plasmocytomas. 11, 15, 40, 41 A large study of 180 patients has shown that CFU-mega and BFU-E may already be altered before transplantation probably due to preceding induction chemotherapies. 42 In agreement with these results the present study shows a stepwise reduction of stem cell yield after consecutive consolidation chemotherapies as a correlate for chemotherapy-associated pregraft stem cell damage. In contrast, the intraindividual stability of the ratios CFU-mega/CFU argues in favor for the presence of MDS-like alterations at diagnosis.
In summary, our study gives the first evidence of the superior prognostic value of MRD detection in the transplant rather than in the pregraft bone marrow and of the possible presence of morphologically, immunophenotypically and cytogenetically undetectable, MDS-like alterations (pre-MDS) in the transplants of de novo AML cases with high probability of relapse. Both of these transplant characteristics may have multifold implications for the design of risk-adapted chemotherapy strategies and for purging of LPs in AML patients.
